NEW YORK, NY / ACCESS Newswire / September 12, 2025 / If you suffered a loss on your Fiserv, Inc. (NYSE:FI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/fiserv-inc-lawsuit-submission-form?prid=166842&wire=1&utm_campaign=10 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call […]

The 2025 Asian Rowing U-19&U-23 Championships concluded on August 31 in Shenyang, northeast China's Liaoning Province. https://mma.prnewswire.com/media/2771834/pic_U19.jpg Hosted by the Asian Rowing Federation and jointly organized by the Chinese Rowing Association and the Shenyang sports bureau, the event featured two age categories: U19 (under 19 years old) and U23 (under 23 years old). A total

NEW YORK, NY / ACCESS Newswire / September 12, 2025 / If you suffered a loss on your PubMatic, Inc. (NASDAQ:PUBM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/pubmatic-inc-lawsuit-submission-form?prid=166827&wire=1&utm_campaign=21 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call

Polyrizon Reports Successful Intranasal Delivery of PL-14 Allergy Blocker in Latest Study GlobeNewswire September 12, 2025 Ra'anana, Israel, Sept. 12, 2025 (GLOBE NEWSWIRE) — Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a biotechnology company focusing on the development of intranasal products, today announced encouraging preclinical results supporting the performance of its PL-14 Allergy Blocker,

NEW YORK, NY / ACCESS Newswire / September 12, 2025 / If you suffered a loss on your Flywire Corporation (NASDAQ:FLYW) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/flywire-corporation-lawsuit-submission-form?prid=166833&wire=1&utm_campaign=29 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call

NEW YORK, NY / ACCESS Newswire / September 12, 2025 / If you suffered a loss on your Nutex Health Inc. (NASDAQ:NUTX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/nutex-health-inc-lawsuit-submission-form?prid=166832&wire=1&utm_campaign=2 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or

NEW YORK, NY / ACCESS Newswire / September 12, 2025 / If you suffered a loss on your Dow Inc. (NYSE:DOW) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/dow-inc-lawsuit-submission-form?prid=166831&wire=1&utm_campaign=15 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call

NEW YORK, NY / ACCESS Newswire / September 12, 2025 / If you suffered a loss on your Replimune Group, Inc. (NASDAQ:REPL) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/replimune-group-inc-lawsuit-submission-form?prid=166841&wire=1&utm_campaign=25 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or

NEW YORK, NY / ACCESS Newswire / September 12, 2025 / If you suffered a loss on your Altimmune, Inc. (NASDAQ:ALT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/altimmune-inc-lawsuit-submission-form-2?prid=166826&wire=1&utm_campaign=15 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call

NEW YORK, NY / ACCESS Newswire / September 12, 2025 / If you suffered a loss on your Neogen Corporation (NASDAQ:NEOG) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/neogen-corporation-lawsuit-submission-form?prid=166825&wire=1&utm_campaign=18 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call